Rich A. Silva, Ph.D., is the Senior Vice President of Technical Operations at LB Pharmaceuticals. With over 25 years of experience in CMC development, GMP manufacturing, quality, and supply chain, he is a proven leader in pharmaceutical sciences, driving drug development strategies from early clinical stages through commercialization. His expertise lies in integrating technological innovation with business strategy to ensure efficient, high-quality, and compliant product development.
Before joining LB Pharmaceuticals, Rich served as Senior Vice President of Pharmaceutical Sciences at Carmot Therapeutics (now part of Roche). There, he led the expansion of the CMC group, overseeing drug substance and product development, device and combination product development, analytical strategies, supply chain, and regulatory compliance. His leadership was instrumental in Carmot’s successful acquisition by Roche, streamlining integration and enhancing operational efficiency.
Previously, he held key leadership roles at Epizyme and ImmunoGen, where he managed technical operations, optimized manufacturing processes, and led regulatory filings. His strategic approach to process development, manufacturing and validation, cost reduction, supply partnerships, supply chain management, quality oversight, and regulatory compliance has contributed to the successful commercialization of multiple therapies, including Tazverik and Elahere™.
Rich holds a Ph.D. in Synthetic Organic Chemistry from Dartmouth College and a B.S. in Chemistry from the University of Massachusetts. A recognized expert in pharmaceutical manufacturing, quality, supply chain, and regulatory strategy, he remains committed to driving innovation and operational excellence in the industry.
